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Purpose
• To examine the efficacy of newly developed, 
polynuclear platinum agents, that work by a similar 
mechanism of damaging DNA cross-linking. 
• Recently, platinum agents are demonstrating to be 
an effective therapy against advanced metastatic 
cancer, though limited by the severe side effects. 
• New platinum derivative compounds were developed 
to have less cytotoxicity, to overcome the severe 
dose dependent toxicities of the former platinum 
agents. 
• Triplatin and Triplatin NC suppressed cell growth of both Breast Cancer and Pancreatic Cancer in a dose dependent manner in vitro. 
• Both Triplatin and TriplatinNC demonstrated growth suppression of the primary breast tumor. A single animal (in the Triplatin NC group) was sacrificed due to weight loss.
• In the advanced ex vivo lung metastasis model our most striking results were observed, where the agents nearly prohibited lung metastasis from occurring. 
• In the pancreatic cancer peritoneal carcinomatosis model, Triplatin reduced total tumor burden. Mouse survival was significantly enhanced by the Triplatin treatment group 
and no mouse developed weight loss more than 25% of body weight. 
• The new platinum compounds with less cytotoxicity and favorable pharmacokinetics warrant further investigation to determine their role in advanced metastatic breast cancer 
and pancreatic carcinomatosis. 
Background
Methods
• In vitro: Cell proliferations were quantified by CCK8 
assay to determine IC50 and drug sensitivity of 4T1-
luc2 cells as a murine breast cancer, and Panc02-luc 
cells as a murine pancreatic cancer. 
• In vivo 4T1 Implantation: Female Balb/C mice were 
orthotopically implanted with murine 4T1-luc2 cells 
(1.0 x 104 cells suspended in 20 µL 1:9, 
PBS:Matrigel) into Rt #2 Mammary Fat Pad ODV. 
Mice were randomized 24-hours after implantation 
into 3 groups based on tumor size (defined as day 1). 
Animals were treated q4 days by I.P. injection with 
either Triplatin (0.3mg/kg), Triplatin NC (25mg/kg), or 
Saline. Primary tumor growth was monitored by 
direct caliper measurement and bioluminescent 
imaging by injecting D-Luciferin (0.2mL) and analysis 
of photon emission with Living Image Software.
• Ex vivo 4T1 Lung Metastasis: Mice were injected 
with I.P. luciferon and sacrificed 10 minutes after 
injection. The lungs were excised and placed in 
sterile 10cm petri dish. Lungs were imaged at a fixed 
time point (15 minutes) post injection.
• In vivo Panc02 Carcinomatosis Implantation: 
Generated by I.P. injection of I x 106 Panc02-luc cells 
into C57/Blk6 mice. Animals were randomized and 
treated q4 days with either Triplatin or saline by I.P. 
injection. Survival was monitored. 
Conclusion & Recommendations 
Results
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Triplatin and Triplatin NC suppressed cell growth 
of both Breast Cancer and Pancreatic Cancer in a 
dose dependent manner in vitro
Triplatin Triplatin NC
Triplatin and Triplatin NC suppressed
primary Breast Cancer tumor growth and developing lung 
metastasis in vivo
Triplatin treatment prolonged survival significantly 
in the Pancreatic Cancer Carcinomatosis 
model in vivo
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